2024-11-0920212211-034810.1016/j.msard.2020.1025812-s2.0-85092918761http://dx.doi.org/10.1016/j.msard.2020.102581https://hdl.handle.net/20.500.14288/10911N/AClinical neuropsychologyMyelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey (vol 44, 102376, 2020)Other2211-0356660293800009Q29151